Testosterone Replacement Therapy and Risk of COVID-19 and Effect of COVID-19 on Testosterone's Treatment Effect
In men with hypogonadism and cardiovascular disease (CVD) or increased risk of CVD, baseline and pre-COVID-19 on-treatment testosterone, dihydrotestosterone, and estradiol levels were similar in those who developed COVID-19 and those who did not. TRT did not affect the risk of COVID-19. COVID-19 attenuated the treatment response to TRT.
Authors
- Eric A. Klein (ORCID: https://orcid.org/0000-0002-1783-0698)
- A. Michael Lincoff (ORCID: https://orcid.org/0000-0001-8175-2121)
- Karol M. Pencina (ORCID: https://orcid.org/0000-0003-1824-7047)
- Shalender Bhasin (ORCID: https://orcid.org/0000-0002-3982-6200)
- Michael G. Miller (ORCID: https://orcid.org/0000-0001-6597-0727)
- Xue Li (ORCID: https://orcid.org/0000-0002-3072-0573)
- Anna Chan
- Yili Valentine Shang
- Steven E. Nissen
- Nader Khan
Institutions
- Brigham and Women's Hospital (US)
- Cleveland Clinic (US)
- Harvard University (US)
- AbbVie (United States) (US)
- Center for Clinical Research (United States) (US)
Publication Details
- Journal
- Journal of the Endocrine Society
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1210/jendso/bvaf002
- Citations
- 6
- Primary Topic
- Hormonal and reproductive studies
- Type
- article
- Field-Weighted Citation Impact
- 7.77
Funders
- AbbVie
- Upsher-Smith
- National Institute on Aging